Advanced search
Combine gene, variant, phenotype, region and year filters
Every result shows the extracted entities next to the sentences that support them; rows for the searched entities come first.
Transparent by designEvery result links extracted entities to its source sentence and publication identifier.
Knowledge-base search
About your search
PCSK9 and dyslipidemia are reported together in 10 articles.
Gene
PCSK9
- HGNC
- HGNC:20001
66articles
66mentions
9variants with confirmed gene link
Most co-reported phenotypes (articles)
familial hypercholesterolemia 25dyslipidemia 10diabetes mellitus 7myocardial infarction 7coronary artery disease 4stroke 3hypertension 2obesity 2
Reported variants (articles · ClinVar status)
Phenotype
Dyslipidemia
338articles
338mentions
12co-reported genes shown
Most co-reported genes (articles)
Counts are literature co-mentions in SaudiVarKB, not clinical or causal assertions. Gene details: HGNC; variant status: ClinVar via dbSNP.
Publications
10 records shown · first 60Epiafzelechin, a Flavanol, Regulates Lipid Homeostasis Through Modulation of HMGCR, PCSK9, and PPAR-α: Mechanistic Insights and Therapeutic Implications.
PMID 41613269 | PMCID PMC12849214 | DOI 10.1155/cdr/9082023 · Cardiovascular therapeutics · 2026 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “Epiafzelechin, a Flavanol, Regulates Lipid Homeostasis Through Modulation of HMGCR, PCSK9, and PPAR-α: Mechanistic Insights and Therapeutic Implications.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “Hyperlipidemia remains a leading modifiable risk factor for cardiovascular morbidity and mortality.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | HMGCR | “Epiafzelechin, a Flavanol, Regulates Lipid Homeostasis Through Modulation of HMGCR, PCSK9, and PPAR-α: Mechanistic Insights and Therapeutic Implications.” | 0.98 | hgnc_dict_v1 |
| gene | LDLR | “Functional enrichment and PPI analysis highlighted HMGCR, PCSK9, PPAR-α, and LDLR as key targets.” | 0.98 | hgnc_dict_v1 |
The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.
PMID 41740668 | DOI 10.1016/j.mvr.2026.104925 · Microvascular research · 2026 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “The possible role of PCSK9 inhibitors in cardiac syndrome X: Bridging microvascular dysfunction, endothelial pathobiology, and molecular pharmacotherapy.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) has emerged as a pivotal mediator linking dyslipidemia to endothelial dysfunction, oxidative injury, and vascular inflammation.” | 0.98 | phenotype_alias_lexicon_v2 |
Whole exome sequencing identifies concurrent LDLR and ABCG8 mutations in a Saudi family with familial hypercholesterolemia and Sitosterolaemia.
PMID 41170196 | PMCID PMC12571453 | DOI 10.3389/fgene.2025.1679594 · Frontiers in genetics · 2025 · 8 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “The proband responded remarkably to ezetimibe monotherapy, while his children required combination therapy with high-intensity rosuvastatin and PCSK9 inhibitor Evolocumab for LDL-C reduction.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “This unique case highlights the complex diagnostic challenges and therapeutic considerations in managing overlapping dyslipidemia phenotypes.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | LDLR | “Whole exome sequencing identifies concurrent LDLR and ABCG8 mutations in a Saudi family with familial hypercholesterolemia and Sitosterolaemia.” | 0.98 | hgnc_dict_v1 |
| gene | ABCG8 | “Whole exome sequencing identifies concurrent LDLR and ABCG8 mutations in a Saudi family with familial hypercholesterolemia and Sitosterolaemia.” | 0.98 | hgnc_dict_v1 |
Charantin targets HMGCR-PCSK9 axis and activates PPAR-α signaling to ameliorate hyperlipidemia: Mechanistic insights from bioinformatics and in-vivo studies.
PMID 40892857 | PMCID PMC12404445 | DOI 10.1371/journal.pone.0331356 · PloS one · 2025 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “Molecular docking studies assessed charantin's binding interactions with key lipid-regulating proteins (HMGCR, PCSK9, LDLR, PPAR-α, PI3K).” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “Charantin targets HMGCR-PCSK9 axis and activates PPAR-α signaling to ameliorate hyperlipidemia: Mechanistic insights from bioinformatics and in-vivo studies.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | HMGCR | “Molecular docking studies assessed charantin's binding interactions with key lipid-regulating proteins (HMGCR, PCSK9, LDLR, PPAR-α, PI3K).” | 0.98 | hgnc_dict_v1 |
| gene | LDLR | “Molecular docking studies assessed charantin's binding interactions with key lipid-regulating proteins (HMGCR, PCSK9, LDLR, PPAR-α, PI3K).” | 0.98 | hgnc_dict_v1 |
Fair pricing, fair access; a systematic review of cost-effectiveness of new hyperlipidemia injectable medication in developing countries.
PMID 41272757 | PMCID PMC12639994 | DOI 10.1186/s12962-025-00671-3 · Cost effectiveness and resource allocation : C/E · 2025 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors (alirocumab, evolocumab) and inclisiran offer greater low-density lipoprotein cholesterol (LDL-C) reduction and improved outcomes beyond statins and ezetimibe, but high costs raise affordability concerns in low- and middle-income countries.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “Fair pricing, fair access; a systematic review of cost-effectiveness of new hyperlipidemia injectable medication in developing countries.” | 0.93 | phenotype_alias_lexicon_v2 |
| phenotype | familial hypercholesterolemia | “Evolocumab was not cost-effective in Chinese post-myocardial infarction (MI) patients (ICERs up to $281,762/QALY) but favorable in familial hypercholesterolemia(FH) ($57,018/QALY), and when evolocumab added to statins was cost-effective in patients with acute MI ($7,819 to $61,242 per QALY) and acute coronary syndrome (ACS) (vs. ezetimibe + statins) ($26,110/QALY) and atherosclerotic cardiovascular disease (ASCVD) (vs. placebo + statins)($4,268/QALY).” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | myocardial infarction | “Evolocumab was not cost-effective in Chinese post-myocardial infarction (MI) patients (ICERs up to $281,762/QALY) but favorable in familial hypercholesterolemia(FH) ($57,018/QALY), and when evolocumab added to statins was cost-effective in patients with acute MI ($7,819 to $61,242 per QALY) and acute coronary syndrome (ACS) (vs. ezetimibe + statins) ($26,110/QALY) and atherosclerotic cardiovascular disease (ASCVD) (vs. placebo + statins)($4,268/QALY).” | 0.93 | phenotype_alias_lexicon_v2 |
Combining In Vitro, In Vivo, and In Silico Approaches to Explore the Effect of Ceratonia siliqua and Ocimum basilicum Rich Phenolic Formula on Lipid Metabolism and Plasma Lipoprotein Oxidation in Mice Fed a High-Fat Diet: A Follow-Up Study.
PMID 39852379 | PMCID PMC11767511 | DOI 10.3390/metabo15010036 · Metabolites · 2025 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “This includes the HMG-CoA reductase, PPARα/γ, PCSK9, Cyp7a1, and ATP-citrate lyase.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “BACKGROUND/OBJECTIVES: Hyperlipidemia is a serious risk factor for cardiovascular diseases and liver steatosis.” | 0.93 | phenotype_alias_lexicon_v2 |
Oxidative Stress, Inflammation, and Altered Lymphocyte E-NTPDase Are Implicated in Acute Dyslipidemia in Rats: Protective Role of Arbutin.
PMID 39458984 | PMCID PMC11509952 | DOI 10.3390/ph17101343 · Pharmaceuticals (Basel, Switzerland) · 2024 · 7 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “The biochemical findings were supported by in silico data showing the affinity of ARB to bind LDL-R PCSK9 binding domain, HMGCR, FAS, and E-NTPDase.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “Oxidative Stress, Inflammation, and Altered Lymphocyte E-NTPDase Are Implicated in Acute Dyslipidemia in Rats: Protective Role of Arbutin.” | 0.98 | phenotype_alias_lexicon_v2 |
| gene | HMGCR | “ARB ameliorated the circulating lipids and LPL, and suppressed 3-hydroxy-3-methylglutaryl CoA reductase (HMGCR) in rat liver and in vitro.” | 0.98 | hgnc_dict_v1 |
| gene | FAS | “Fatty acid synthase (FAS) in rat liver and its in vitro activity were suppressed by ARB, which also upregulated the LDL receptor (LDL-R) and ABCA1, and had no effect on ABCG5 and ABCG8 mRNA.” | 0.98 | hgnc_dict_v1 |
Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection.
PMID 38528584 | PMCID PMC10962113 | DOI 10.1186/s12934-024-02355-8 · Microbial cell factories · 2024 · 5 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “Potential use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and prevention method in viral infection.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “In addition to the current inquiry into the potential therapeutic application of PCSK9 inhibition in human immunodeficiency virus (HIV)-infected patients for hyperlipidemia associated with HIV and antiretroviral therapy (ART), preclinical research suggests that PCSK9 may also play a role in inhibiting hepatitis C virus (HCV) replication.” | 0.93 | phenotype_alias_lexicon_v2 |
| gene | LDLR | “The pivotal role that proprotein convertase subtilisin/kexin Type 9 (PCSK9) plays in cholesterol homeostasis and atherosclerosis, primarily by post-transcriptionally regulating hepatic low-density lipoprotein receptor (LDLR) and promoting its lysosomal degradation, has garnered increasing interest.” | 0.98 | hgnc_dict_v1 |
| phenotype | hepatitis C | “In addition to the current inquiry into the potential therapeutic application of PCSK9 inhibition in human immunodeficiency virus (HIV)-infected patients for hyperlipidemia associated with HIV and antiretroviral therapy (ART), preclinical research suggests that PCSK9 may also play a role in inhibiting hepatitis C virus (HCV) replication.” | 0.98 | phenotype_alias_lexicon_v2 |
Genetics, Safety, Cost-Effectiveness, and Accessibility of Injectable Lipid-Lowering Agents: A Narrative Review.
PMID 36935878 | PMCID PMC10017216 | DOI 10.1155/2023/2025490 · Journal of lipids · 2023 · 2 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “Alternatives to statins are PCSK9 inhibitors which are administered subcutaneously every two or four weeks.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “Dyslipidemia has proven to be a major factor that contributes to its increased incidence; thus, since a long time, low-density lipoprotein cholesterol-lowering therapies have been employed to reduce coronary artery disease-associated mortality.” | 0.98 | phenotype_alias_lexicon_v2 |
Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia.
PMID 28163543 | PMCID PMC5242035 | DOI 10.4103/0976-500X.195906 · Journal of pharmacology & pharmacotherapeutics · 2016 · 3 validated mentions
Evidence preview
| Type | Entity | Source evidence | Confidence | Extractor |
|---|---|---|---|---|
| gene | PCSK9 | “The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market.” | 0.98 | hgnc_dict_v1 |
| phenotype | dyslipidemia | “Proprotein convertase subtilisin/kexin type 9 enzyme inhibitors: An emerging new therapeutic option for the treatment of dyslipidemia.” | 0.98 | phenotype_alias_lexicon_v2 |
| phenotype | familial hypercholesterolemia | “The treatment of hypercholesterolemia entered in a new phase of development with the introduction of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in the market.” | 0.93 | phenotype_alias_lexicon_v2 |